跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE
Authorized
STANDARD
AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE
angita pharma inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
dd7fa57909f2afee
Company
angita pharma inc.
Type
Standard
Approval Details
Approval Id
dd7fa57909f2afee
Drug Approval Canada Name
AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE
Product Name
AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE
Status
Marketed
Status Date
2020-11-09
Original Market Date
2020-11-09
Din
02496356
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AR03 TENOFOVIR DISOPROXIL AND EMTRICITABINE
Atc Name
j 05 ar 03
Aig Number
0251568001
Company Name
angita pharma inc.
Company Address
1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3
Active Ingredients
EMTRICITABINE
200 MG
TENOFOVIR DISOPROXIL FUMARATE
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
dd7fa57909f2afee
Type
Standard
Back to Health Canada Approvals
